



Level 1, 3-5 George Street
Leichhardt
NSW 2040
Australia

+61 (0)2 9099 4750
info@atomodiagnostics.com

30 December 2021

ASX Limited
Mr Adrian Smythe
Manager, Listings Compliance (Sydney)
20 Bridge Street
Sydney NSW 2000
By email to: ListingsComplianceSydney@asx.com.au

Dear Mr Smythe

ASX PRICE QUERY

We refer to your letter dated 29 December 2021 regarding the increase in price and volume traded of securities in Atomo Diagnostics Limited (**Atomo**) and set out below our responses to your questions and requests for information:

1. No, Atomo is not aware of any information concerning it that has not been announced to the market which could explain the recent trading in Atomo securities.
2. Not applicable.
3. Atomo is aware of an article in The Australian yesterday, 29 December 2021, which referenced the Company, and an increase in media attention on COVID-19 rapid antigen testing generally including: an article in the Sydney Morning Herald on 28 December 2021 titled '*States fight for rapid antigen test supplies as federal government sits back*'; and a further article yesterday titled '*Gear change: Close contact definition changes and more rapid antigen tests amid Omicron surge*,' which detailed amongst other things that the NSW government had secured 20 million rapid antigen tests and that Victoria had announced it had bought 34 million kits.

Atomo announced on 5 October 2021 a new agreement with Access Bio LLC which provides Atomo with the right to purchase up to 10 million COVID-19 rapid antigen tests for use in professional settings and 10 million COVID-19 rapid antigen self-tests (20 million tests in total). As stated in Atomo's announcement, the use in Australia of the COVID-19 rapid antigen self-test is subject to TGA approval.

4. Atomo confirms that it is in compliance with the Listing Rules and in particular Listing Rule 3.1.
5. Atomo confirms that its responses above have been authorised and approved by the Board.

Yours sincerely,

Gillian Nairn
Company Secretary



29 December 2021

Reference: 44795

Ms Gillian Nairn
Company Secretary
Atomo Diagnostics Limited

By email:

Dear Ms Nairn

Atomo Diagnostics Limited ('AT1'): Price - Query

ASX refers to the following:

- A. The change in the price of AT1's securities from a close of \$0.21 on 24 December 2021 to a high of \$0.285 today at the time of writing.
- B. The significant increase in the volume of AT1's securities traded today.

Request for information

In light of this, ASX asks AT1 to respond separately to each of the following questions and requests for information:

1. Is AT1 aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
 - (a) Is AT1 relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in AT1's securities would suggest to ASX that such information may have ceased to be confidential and therefore AT1 may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that AT1 may have for the recent trading in its securities?
4. Please confirm that AT1 is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that AT1's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of AT1 with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9:30 AM AEDT Thursday, 30 December 2021**. You should note that if the

information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, AT1's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require AT1 to request a trading halt immediately.

Your response should be sent to me by e-mail at ListingsComplianceSydney@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in AT1's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in AT1's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to AT1's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that AT1's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

Adrian Smythe
Manager, Listings Compliance (Sydney)

CC: Mr John Kelly, Atomo Diagnostics Limited